Bill Gates and rich al­lies help fund an alt-biotech start­up path for the gene ex­pres­sion ex­perts at Ex­i­cure

Ex­i­cure CEO David Giljo­hann has been busy.

In the past cou­ple of months, he’s round­ed up two tranch­es of cash to­tal­ing $31.5 mil­lion from a grow­ing band of back­ers, with Bill Gates com­ing back to join new, wealthy in­vestor Fred Knoll in a syn­di­cate that has strayed far off the typ­i­cal start­up fund­ing path in biotech.

But that’s not his on­ly di­ver­gence from the stan­dard course. He’s ex­e­cut­ed a “clean” re­verse merg­er with a com­plete­ly emp­ty shell to go out on­to the OTC mar­ket — not Nas­daq. And, back in the norm, he’s fol­lowed up on his first round of Phase I da­ta with plans to line up a se­ries of Phase II stud­ies to put his plat­form tech to a cru­cial test.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.